First randomized placebo-controlled trial in NTM abscessusSymptom-based endpoints showed favorable improvement in frequency and severity of the most common symptomsMicrobiologic endpoints showed higher conversion to negative sputum culture, without emergence of resistance to omadacyclineIn this 12-week study, omadacycline appeared to be safe and well-tolerated with no new or unexpected safety signals BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutica ...